Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting

Perrone V
Sangiorgi D
Buda S
Degli Esposti L

November 2016

Valentina Perrone, Diego Sangiorgi, Stefano Buda, Luca Degli Esposti CliCon S.r.l. Health, Economic...

Pharmacoeconomic assessment of dual bronchodilation therapy in patients with COPD

Zyryanov S.K.
D'yakov I.N.

March 2020

This study was aimed at clinical and economic assessment of feasibility of inclusion glycopyrronium ...

Clinically relevant and economic outcomes of maintenance pharmacotherapy in chronic obstructive pulmonary disease (COPD)

D\u27Souza, Anna O.

December 2006

COPD is ranked as the fourth leading cause of death with an estimated cost of {dollar}37.2 billion i...

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Darbà, Josep
Ramírez, Gabriela
García-Rivero, Juan L.
Mayoralas, Sagrario
Pascual, José Francisco
Vargas, Diego
Bijedic, Adi

March 2017

The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spir...

Economic Impact of Low Adherence to COPD Management Guidelines in Spain

Miravitlles Fernández, Marc
Solé, Alexandra
Aguilar, Helena
Ampudia, Ana
Costa-Samarra, Jaume
Mallén-Alberdi, Maria

November 2021

Enfermedad pulmonar obstructiva crónica; Recomendaciones; TratamientoChronic obstructive pulmonary d...

A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions

Darbà, Josep
Ramírez, Gabriela
García-Rivero, Juan L.
Mayoralas, Sagrario
Pascual, José Francisco
Roger, Albert
Vargas, Diego
Bijedic, Adi

To assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potenti...

Budesonide + formoterol delivered via Spiromax(R) for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler(R)

Lewis, A.
Torvinen, S.
Dekhuijzen, P.N.R.
Chrystyn, H.
Melani, A.
Zollner, Y.
Kolbe, K.
Watson, A.T.
Blackney, M.
Plich, A.

January 2017

Contains fulltext : 178199.pdf (Publisher’s version ) (Open Access)BACKGROUND: Fix...

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

Löfdahl, Claes-Göran
Ericsson, A
Svensson, K
Andreasson, E

January 2005

Objective: To compare the healthcare costs and effects of budesonide/formoterol in,a single inhaler ...

Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS

Vallejo-Aparicio LA
Peces-Barba G
Gil A
Huerta Hernandez A

September 2018

Laura Amanda Vallejo-Aparicio,1 Germán Peces-Barba,2 Alicia Gil,3 Alicia Huerta Hernandez1 1M...

Real-world evidence effect of budesonide+formoterol Spiromax on patients with asthma and chronic obstructive pulmonary disease in Sweden

Jansson, Christer
Benhaddi, Hicham
Törnblom, Michael
Uhde, Milica
Johansson, Gunnar

January 2019

Background and Objective: Despite improved asthma and chronic obstructive pulmonary disease (COPD) m...

Economic Evaluation of Treating Chronic Obstructive Pulmonary Disease: The Effects of Early Initiation of Inhaled Corticosteroids on Exacerbation Risks, Utilization and Costs

Akazawa, Manabu

May 2007

Chronic obstructive pulmonary disease (COPD) is a slowly progressive disease of airway obstruction. ...

Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: A cost-effectiveness analysis

Boven, Job
Tommelein, Eline
Boussery, Koen
Mehuys, Els
Vegter, P.C.
Brusselle, Guy
Rutten-van Mölken, Maureen
Postma, Maarten

June 2014

Background: The PHARMACOP-intervention significantly improved medication adherence and inhalation te...

A budget impact analysis of Spiromax® compared with Turbuhaler® for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions

Darb&agrave
Ram&iacute
Garc&iacute
Mayoralas-Alises S
Pascual JF
Roger A,Vargas D
Bijedic A

September 2016

Josep Darbà,1 Gabriela Ramírez,2 Juan L García-Rivero,3 Sagrario Mayoralas-Alis...

Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

Nielsen, Rune
Kankaanranta, Hannu
Bjermer, Leif
Lange, Peter
Arnetorp, Sofie
Hedegaard, Morten
Stenling, Anna
Mittmann, Nicole

January 2013

Objective: Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler®+tiotropium ...

Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR’s guidance on budget impact in practice

Fens, T.
van der Pol, S.
Kocks, Janwillem W.H.
Postma, Maarten J.
van Boven, Job F.M.

October 2019

Objectives To assess the budget impact of restricting inappropriate inhaled corticosteroids (ICS) us...

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting

Perrone V
Sangiorgi D
Buda S
Degli Esposti L

November 2016

Valentina Perrone, Diego Sangiorgi, Stefano Buda, Luca Degli Esposti CliCon S.r.l. Health, Economic...

Pharmacoeconomic assessment of dual bronchodilation therapy in patients with COPD

Zyryanov S.K.
D'yakov I.N.

March 2020

This study was aimed at clinical and economic assessment of feasibility of inclusion glycopyrronium ...

Clinically relevant and economic outcomes of maintenance pharmacotherapy in chronic obstructive pulmonary disease (COPD)

D\u27Souza, Anna O.

December 2006

COPD is ranked as the fourth leading cause of death with an estimated cost of {dollar}37.2 billion i...

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Darbà, Josep
Ramírez, Gabriela
García-Rivero, Juan L.
Mayoralas, Sagrario
Pascual, José Francisco
Vargas, Diego
Bijedic, Adi

March 2017

The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spir...

Economic Impact of Low Adherence to COPD Management Guidelines in Spain

Miravitlles Fernández, Marc
Solé, Alexandra
Aguilar, Helena
Ampudia, Ana
Costa-Samarra, Jaume
Mallén-Alberdi, Maria

November 2021

Enfermedad pulmonar obstructiva crónica; Recomendaciones; TratamientoChronic obstructive pulmonary d...

A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions

Darbà, Josep
Ramírez, Gabriela
García-Rivero, Juan L.
Mayoralas, Sagrario
Pascual, José Francisco
Roger, Albert
Vargas, Diego
Bijedic, Adi

To assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potenti...

Budesonide + formoterol delivered via Spiromax(R) for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler(R)

Lewis, A.
Torvinen, S.
Dekhuijzen, P.N.R.
Chrystyn, H.
Melani, A.
Zollner, Y.
Kolbe, K.
Watson, A.T.
Blackney, M.
Plich, A.

January 2017

Contains fulltext : 178199.pdf (Publisher’s version ) (Open Access)BACKGROUND: Fix...

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

Löfdahl, Claes-Göran
Ericsson, A
Svensson, K
Andreasson, E

January 2005

Objective: To compare the healthcare costs and effects of budesonide/formoterol in,a single inhaler ...

Cost–consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS

Vallejo-Aparicio LA
Peces-Barba G
Gil A
Huerta Hernandez A

September 2018

Laura Amanda Vallejo-Aparicio,1 Germán Peces-Barba,2 Alicia Gil,3 Alicia Huerta Hernandez1 1M...

Real-world evidence effect of budesonide+formoterol Spiromax on patients with asthma and chronic obstructive pulmonary disease in Sweden

Jansson, Christer
Benhaddi, Hicham
Törnblom, Michael
Uhde, Milica
Johansson, Gunnar

January 2019

Background and Objective: Despite improved asthma and chronic obstructive pulmonary disease (COPD) m...

Economic Evaluation of Treating Chronic Obstructive Pulmonary Disease: The Effects of Early Initiation of Inhaled Corticosteroids on Exacerbation Risks, Utilization and Costs

Akazawa, Manabu

May 2007

Chronic obstructive pulmonary disease (COPD) is a slowly progressive disease of airway obstruction. ...

Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: A cost-effectiveness analysis

Boven, Job
Tommelein, Eline
Boussery, Koen
Mehuys, Els
Vegter, P.C.
Brusselle, Guy
Rutten-van Mölken, Maureen
Postma, Maarten

June 2014

Background: The PHARMACOP-intervention significantly improved medication adherence and inhalation te...

A budget impact analysis of Spiromax® compared with Turbuhaler® for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions

Darb&agrave
Ram&iacute
Garc&iacute
Mayoralas-Alises S
Pascual JF
Roger A,Vargas D
Bijedic A

September 2016

Josep Darbà,1 Gabriela Ramírez,2 Juan L García-Rivero,3 Sagrario Mayoralas-Alis...

Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

Nielsen, Rune
Kankaanranta, Hannu
Bjermer, Leif
Lange, Peter
Arnetorp, Sofie
Hedegaard, Morten
Stenling, Anna
Mittmann, Nicole

January 2013

Objective: Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler®+tiotropium ...

Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR’s guidance on budget impact in practice

Fens, T.
van der Pol, S.
Kocks, Janwillem W.H.
Postma, Maarten J.
van Boven, Job F.M.

October 2019

Objectives To assess the budget impact of restricting inappropriate inhaled corticosteroids (ICS) us...

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting

Perrone V
Sangiorgi D
Buda S
Degli Esposti L

November 2016

Valentina Perrone, Diego Sangiorgi, Stefano Buda, Luca Degli Esposti CliCon S.r.l. Health, Economic...

Pharmacoeconomic assessment of dual bronchodilation therapy in patients with COPD

Zyryanov S.K.
D'yakov I.N.

March 2020

This study was aimed at clinical and economic assessment of feasibility of inclusion glycopyrronium ...

Clinically relevant and economic outcomes of maintenance pharmacotherapy in chronic obstructive pulmonary disease (COPD)

D\u27Souza, Anna O.

December 2006

COPD is ranked as the fourth leading cause of death with an estimated cost of {dollar}37.2 billion i...

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Abstract

Extracted data

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Abstract

Extracted data

Related items

Related items